Brief: Eloxx Pharmaceuticals Opens Clinical Trial Sites For Mid-Stage Study of Alport Syndrome Therapy
01/11/2022 21:28
Nov 1 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS ANNOUNCES OPENING OF CLINICAL TRIAL
SITES
FOR PHASE 2 STUDY OF ELX-02 FOR THE TREATMENT OF ALPORT SYNDROME
Source text for Eikon: ID:nGNX3JfG4b
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))